GLP - 1 Analogs: Newer Molecules, Newer Uses

Authors: Kalra, Sanjay; Kalra, Bharti; Kumar, Amit

Source: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Volume 3, Number 2, June 2009 , pp. 129-134(6)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $104.88 plus tax (Refund Policy)

Abstract:

Much interest has focused on the newer incretin-based therapeutic modalities for diabetes, especially GLP-1 analogues. While the comparatively older GLP-1 analogs, exenatide and liraglutide, have been discussed extensively in literature, much less is known about the newer GLP-1 analogues in the pipeline. This review focuses on the newer molecules being studied, the newer routes of administration being tried, some recent patents and potential uses for these multifaceted compounds.

Keywords: GLP-1 analogs; long acting exenatide; albiglutide; taspoglutide; GLP-2 analogs; GLP-1 secretagogues

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187221409788452309

Publication date: 2009-06-01

More about this publication?

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery publishes review articles by experts on recent patents in the field of endocrine, metabolic and immune drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in endocrine, metabolic and immune drug design and discovery.